Mediar Therapeutics announces $105 million in funding to advance portfolio of best-in-class fibrosis therapies

Mediar Therapeutics announces $105 million in funding to advance portfolio of best-in-class fibrosis therapies

The company is pioneering a novel approach by targeting fibrotic mediators that drive disease progression The portfolio includes three targets,…

Read More »